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A B S T R A C T
Besides its nutritional value, taro (Colocasia esculenta) is traditionally used as a medicinal
plant and provides bioactive compounds with important biological properties. This study
evaluated the in vitro and in vivo immunomodulatory potential of the protein extract from
taro corms on the haematopoietic cells of C57BL/6 and BALB/c mice. The crude taro extract
(CTE) stimulated the in vitro proliferation of mice splenocytes in a dose-dependent manner
in both mice strains. The intraperitoneal inoculation of CTE induced splenomegaly and the
proliferation of total spleen and bone-marrow cells. Additionally, CTE promoted in vivo B220+
splenocyte proliferation, which was accompanied by a reduction of mature (B220+ IgM+) and
immature (B220+ IgM−) B cells in the bone marrow. The production of Antibody by B220+
splenocytes indicated the activation of B1 cells by the CTE only in C57BL/6. CTE represents
a powerful source of immunostimulatory proteins, new candidates as additives for food and
pharmaceutical industries.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
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1. Introduction
To address increasing demand for natural products to benefit
human health, bioactive compounds have been extracted from
a variety of natural sources including animals, plants, algae,
microalgae, microorganisms, food and food by-products
(Herrero, Cifuentes, & Ibanez, 2006). Plants are a rich source
of bioactive phytochemicals, which can occur in different forms,
such as proteins or peptides, carotenoids, polyphenols,
isoflavones and sterols among others (Abuajah, Ogbonna, &
Osuji, 2015).
In plants, such bioactive compounds are used for defence,
exerting pharmacological or toxicological effects in animals and/
or humans. Despite their anti-nutritional value, the beneficial
effects of bioactive compounds in providing protection for the
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health of living beings have stimulated the application of these
molecules in the agricultural and pharmaceutical fields
(Bernhoft et al., 2010; Gupta, Tuohy, O’Donovan, & Lohani, 2015).
Since it is well known that dietary habits are directly related
to human healthmaintenance, the application of bioactive com-
pounds as functional food ingredients hasmet recent consumer
demand for products of natural origin. The consumption of
these products can promote health and well-being by modu-
lating metabolic processes, protecting humans against health
disorders (Mitsuoka, 2014; Plaza, Cifuentes, & Ibáñez, 2008). All
these benefits are triggered by native bioactive compounds and/
or by the addition of new natural compounds, which are now
substituting conventional synthetic ones (Lagos, Vargas, de
Oliveira, da Aparecida Makishi, & do Amaral Sobral, 2015). Phar-
maceutical industries have also taken advantage of bioactive
compounds, which offer a source of powerful candidates to
solve the problems faced by the use of several current drugs,
such as undesirable side effects and microbial resistance
(Bernhoft et al., 2010; Sasidharan, Chen, Saravanan, Sundram,
& Latha, 2011).
Immunostimulators, also called immunomodulators, are an
interesting class of bioactive compounds that can be thor-
oughly used as food additives, at the same time reinforcing
innate immune system responses in human beings. Exten-
sively found in plants, these molecules exert their
pharmacological activity by mimicking cytokine functions,
which are naturally occurring stimulators produced by the cells
of the immune system (Gupta et al., 2015; Kumar, Gupta,
Sharma, & Kumar, 2011). They cause biochemical and func-
tional modifications in these immunocompetent cells
(Shanmugham et al., 2006), playing a critical role in the in-
duction of proliferation, differentiation and cell death (Tulin
& Ecleo, 2007).These compounds can specifically interact with
certain sugars on the cell surface of one or several glycopro-
teins, leading to cell proliferation of different lymphocyte clones
(Shanmugham et al., 2006).
Taro [Colocasia esculenta (L.) Schott; Araceae], an annual her-
baceous plant from tropical and sub-tropical regions (Tarak
et al., 2011) and a member of the Araceae superfamily, is a low-
cost and widely consumed staple food in the human diet (Van
Damme et al., 1995). Its corms provide important nutritional
components such as carbohydrates, protein, thiamine, ribo-
flavin, niacin, oxalic acid, calcium oxalate, minerals, lipids,
unsaturated fatty acids and anthocyanins (Ramos Filho, Ramos,
& Hiane, 1997; Subhash, Sarla, & Jaybardhan, 2012). Taro has
superior nutritional value compared with potato, sweet potato,
cassava and rice.Additionally, what makes taro a valuable edible
plant is the easy digestion of its starch granules and its non-
allergenic properties (Lim, 2015; Prajapati, Kalariya, Umbarkar,
Parmar, & Sheth, 2011).
Additionally, taro has traditionally been used as a medici-
nal plant for curative purposes. A wide variety of bioactive
compounds can be extracted from all plant parts of this species.
These molecules were shown to have important pharmaco-
logical activities including anticancer (Brown, Reitzenstein, Liu,
& Jadus, 2005), antihyperlipidaemic/antihypercholesterolaemic
(Sakano et al., 2005), anxiolytic (Kalariya, Parmar, & Sheth, 2010),
wound healing (Gonçalves et al., 2013), antimelanogenic (Kim,
Moon, Kim, & Lee, 2010), anti-inflammatory (Biren, Nayak, Bhatt,
Jalalpure, & Seth, 2007), probiotic (Brown & Valiere, 2004),
antihypertensive (Vasant et al., 2012), antidiabetic (Eleazu,
Iroaganachi, & Eleazu, 2013; Kumawat, Chaudhari, Wani,
Deshmukh, & Patil, 2010; Li, Hwang, Kang, Hong, & Lim, 2014),
antioxidant (Lee, Wee, Yong, & Syamsumir, 2011),
hepatoprotective (Patil & Ageely, 2011), anti-inflammatory, an-
timicrobial (Dhanraj, Kadam, Patil, & Mane, 2013), anti-
helminthic (Kubde, Khadabadi, Farooqui, & Deore, 2010),
proliferative (Pereira et al., 2014) and hypolipidaemic (Boban,
Nambisan, & Sudhakaran, 2006) properties.
The purpose of this study was to determine the in vitro and
in vivo immunomodulatory potential of the crude protein extract
of taro corms (C. esculenta) on haematopoietic cells from the
spleen and bone marrow, using two distinct murine models,
the C57BL/6 and BALB/c strains.The total number of cells from
spleen and bone marrow were evaluated following crude taro
extract inoculation. Additionally, spleen weight × body weight
was analysed and confronted with spleen cellularity.The in vivo
effects of the crude taro extract on mice B220+ lymphocytes
from both spleen and bonemarrow were also evaluated, as well
as the triggering of antibody production by spleen cells.
2. Materials and methods
2.1. Plant material and animals
C. esculenta (L.) Schott corms were purchased from a local
grocery store in the municipality of Niterói, Brazil. A voucher
specimen was deposited at the RFA Herbarium of the
Universidade Federal do Rio de Janeiro (UFRJ), Centro de Ciências
da Saúde, Departamento de Botânica (Rio de Janeiro, Brazil)
under the designation RFA-39.962 (Fig. S1).
Female inbred C57BL/6 and BALB/c mice (8 weeks old) were
obtained from the Animal Facility at the Universidade Federal
Fluminense (UFF), and were maintained under conventional
environmental conditions with air exhaustion, room tempera-
ture at 23–25 °C, fed Nuvilab CR-1 chow (Nuvital Nutrientes S/A,
Colombo, PR, Brazil) and acidified water ad libitum. The study
protocol was approved by the Institutional Ethics Committee
for Animal Research at the Universidade Federal Fluminense
under number 0019-08.
2.2. Crude taro extract (CTE) preparation
Sliced taro corms were dehydrated overnight at 37 °C in a ven-
tilated incubator. The dried sliced corms were homogenized
(1 g/5 mL) in 0.05 M sodium phosphate buffer pH 7.2 with the
aid of a Waring® blender. The resultant homogenate was in-
cubated overnight at 4 °C under constant shaking. Solid
particulates were removed by filtration in cheesecloth and cen-
trifugation at 28,000 × g for 20 min (IEC – International
Centrifuge, model PR-2, Needham, MA, USA). The superna-
tant, or crude taro extract, was stored at −20 °C until use
(Carneiro, Rodrigues, De Castro, Da Silva, & Coutinho, 1990).
2.3. Determination of protein concentration
Protein concentration in the CTE was estimated by the Lowry
method (Lowry, Rosebrough, Farr, & Randall, 1951), using bovine
serum albumin (BSA) as a standard.
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2.4. Protein profile analysis by SDS-PAGE
Homogeneous 12.5% polyacrylamide gels under denaturing and
reducing conditions were set up according to Laemmli (1970).
Aliquots containing 10 and 15 µg of protein were loaded onto
the SDS-gels and the resolved polypeptide bands were ob-
served by staining the gels with Coomassie® Brilliant Blue G-250
Ultra Pure (USB Corporation, Cleveland, OH, USA) according to
the Kurien and Scofield protocol (Kurien & Scofield, 2012). Mo-
lecular masses of the polypeptide bands were estimated by
comparison to the standard protein markers (PageRuler™ Un-
stained Protein Ladder,Thermo Scientific, Pittsburgh, PA, USA).
The gel figure displayed is representative of multiple experi-
ments. Fractionation on SDS-PAGE gel was a routine step
following extract preparation.
2.5. Mice treatment by inoculation of crude taro extract
One milligram of CTE protein, diluted in 0.5 mL of physiologi-
cal saline solution (0.85% NaCl), was administered
intraperitoneally to C57BL/6 and BALB/c mice (n = 10 per strain).
The control group (n = 5 per strain) received 0.5 mL of physi-
ological saline also by intraperitoneal route (Fig. 1).
Five mice of each strain were sacrificed on the 5th day after
CTE inoculation and the 5 remaining animals from each strain
were sacrificed on the 10th day.
2.5.1. In vivo effect of CTE inoculation on the total number
of bone marrow and spleen cells from treated mice
On the 5th and 10th days after CTE inoculation, mice spleens
were removed and immediately weighed to determine the rela-
tive spleen weight versus body weight. The spleens were
carefully dissociated in Hank’s balanced salt solution (HBSS)
(Sigma-Aldrich, St. Louis, MO, USA) with the aid of a bolter and
syringe plunger to produce a spleen cell suspension.The bone
marrows were also removed and a cell suspension was ob-
tained by percolating the femur several times with HBSS. Both
cell suspensions were washed twice in cold HBSS, centri-
fuged at 258 × g at 4 °C for 7 min and the supernatants were
discarded at the end of the process. Pelleted cells were
submitted to osmotic shock with a hypotonic solution (HBSS
diluted 5× in distilled water) for 10–20 s under manual agita-
tion to eliminate erythrocytes. The erythrocyte-free cell
suspensions were again washed by adding HBSS and centri-
fuging at 258 × g at 4 °C for 7 min. The resulting pellet was
suspended in cold HBSS and maintained on ice.
Suspended splenocytes and bonemarrow cells, in cold HBSS,
were mixed 1:1 (v/v) with 0.4% trypan blue. The mixture was
incubated at room temperature for 3 min after which, viable
(unstained) cells were ready for visualization and counting on
a Neubauer chamber (Labor Optik, Lancing, UK) using optical
microscopy (Olympus BX41 – Olympus America INC, Melville,
NY, USA), as described previously (Strober, 2001). The total
number of viable cells per millilitre was determined by mul-
tiplying the number of counted viable cells by the dilution factor
for trypan blue.
2.5.2. In vivo effect of CTE on B lymphocytes proliferation
To determine the number of B lymphocytes in the spleen and
bone marrow after CTE inoculation, both cell suspensions
(1 × 106 cells) were, separately, incubated in phosphate-
buffered saline (PBS) supplemented with 3% normal mouse
serum for 20 min at 4 °C to block future unspecific antibody
binding.The mixture was then centrifuged at 560 × g for 7 min
at 4 °C and the pellet was suspended in HBSS.
Anti-B220 PE (BD Pharmingen™, San Jose, CA, USA) was
added to the splenocytes to determine the number of prolif-
erating B cells. To analyse mature (B220+IgM+) and immature
(B220+IgM−) B cells, anti-B220 PE and anti-IgM FITC (Southern
Biotechnology Associates Inc., AL, USA) were added to bone-
marrow cells according to the manufacturer’s instructions. PBS
containing 0.001% sodium azide and 3% foetal calf serum (FCS)
was added to the mixture and the cells were incubated in the
dark at 4 °C for 40 min. Excess reagent was eliminated by
washing the cells with cold PBS and the cells were fixed with
1% formalin. Fluorescence intensity was detected in a Flow Cy-
tometer (FACSCalibur, Becton Dickinson, San Jose, CA, USA),
where a gate containing only lymphocytes was selected based
on their size and granularity patterns; the results were analysed
Fig. 1 – Experimental design. Evaluation of CTE effects on haematopoietic cells in two murine models.
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using WinMDI 2.8 software (http://facs.scripps.edu/
software.html).
2.5.3. Plaque-forming cell assay (PFC)
The method already described by Cunningham and Szenberg
(1968) with minor modifications was performed to evaluate
the effect of CTE on the activation of B lymphocytes by the
production of antibodies against bromelain-treated erythro-
cytes (anti-BrMRBC). Spleen cells from CTE-treated mice were
obtained as described previously (section 2.5.1). Briefly, mouse
red blood cells (MRBC) were collected from the caudal vein,
conserved into an anticoagulant solution (3.8% sodium citrate
in physiological saline) and washed in PBS. The MRBC pellet
was mixed with an equal volume of a 10 mg mL−1 bromelain
solution (Sigma-Aldrich Chemicals), incubated for 30 min at
37 °C, washed in PBS and suspended in HBSS, resulting
in a 20% (v/v) bromelain-treated MRBC suspension (BrMRBC).
Fresh rabbit serum, previously absorbed with BrMRBCs at
4 °C for 30 min, was used as a source of complement system
factors.
A mixture containing 20 µL HBSS, 20 µL rabbit comple-
ment, 10 µL BrMRBC and 50 µL of splenocyte suspension (stock
suspension of 2 × 107 cells/mL) was loaded on a Cunningham–
Szenberg chamber, sealed with paraffin and incubated at 37 °C
for 1 h.The number of plaque-forming cells was counted under
an optical microscope.
2.6. In vitro proliferation assay of mice splenocytes in the
presence of CTE
Splenocytes (4 × 105 per well) from non-inoculated mice were
obtained as described previously (section 2.5.1) and cultured
in 200 µL RPMI-1640 (Sigma-Aldrich Chemicals) complete
medium, supplemented with 10% foetal bovine serum, 2 mM
L-glutamine, 5 × 10−5M β-mercaptoethanol, 20 µg/mL gentami-
cin and increasing amounts of CTE ranging from 100 µg to
0.09 µg. Cells were incubated in 96-well flat-bottom plates (TPP
Techno Plastic Products AG,Trasadingen, Switzerland) for 72 h
at 37 °C in a 5% CO2 atmosphere. To assess proliferation, the
cells were pulsed with 0.5 mCi/well [3H]-thymidine (Amersham
Co., Amersham, UK) 16 h before the end of the culture. At the
end of 72 h, cell suspensions were harvested onto a glass fibre
filter (Titertek, FlowLab, Covina, CA, USA), which was dried and
submerged in liquid scintillationmixture (Sigma-Aldrich Chemi-
cals). Radioactive incorporation was measured on a beta-
irradiation counter (Packard, model 1600C, Fallbrook, CA, USA).
Assays were performed in triplicate and the results were ex-
pressed as scintillations per minute (CPM).
2.7. Statistical analyses
A paired Student’s t test was used to compare the data from
the cell proliferation assay and an ANOVA with Tukey post-
test (Zar, 1984) was used to perform all multiple comparisons
analyses. Significance was considered when p < 0.05, as deter-
mined by the Instat GraphPad Software (GraphPad Software,
Inc., San Diego, CA, USA).
3. Results
3.1. Protein profile of the crude taro extract (CTE)
Each CTE obtained from taro corms was routinely analysed by
12.5% SDS-PAGE to determine its protein composition. Three
major groups of polypeptides, with apparent molecular masses
of approximately 55, 22 and 12 kDa,were visualized (Fig. 2). Each
group was comprised of two polypeptide bands, in agree-
ment with previous results (Hirai, Nakamura, Imai, & Sato, 1993;
Pereira et al., 2014).
Taro corms contain four major protein families, which are
present exclusively in the tubers of C. esculenta, not having been
found in other plant organs (Hirai et al., 1993). Two albumins,
A1 (molecular mass 12 to 14 kDa) and A2 (molecular mass 55
to 66 kDa); and two globulins, G1 (molecular mass about 14 kDa)
and G2 (molecular mass about 22 kDa) are present. The G2
globulin family is composed of two protein bands, one of 24 kDa
(G2a) and one 22 kDa (G2b) in size, whereas G1 is composed
of a large number of 12 kDa isoforms (Pereira et al., 2014;
Shewry, 2003).
The semi-quantitative evaluation of the polypeptide band
intensities on the SDS-PAGE performed by densitometric analy-
sis, using the GelAnalyzer 2010 software (www.gelanalyzer.com),













Fig. 2 – A representative SDS-PAGE (12.5%) analysis of CTE.
The protein profile of each crude extract obtained from taro
corms (Colocasia esculenta) was routinely analysed on a
12.5% SDS-PAGE system. Lane P – molecular mass markers
(PageRuler™ Unstained Protein Ladder, Thermo Scientific);
lanes 1 and 2 – 10 and 15 µg of CTE protein, respectively.
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the G2 globulin group for about 28% while the G1 globulin group
accounts for about 59% of the total CTE protein content.
3.2. In vitro splenocyte proliferation in the presence of
CTE
CTE significantly increased the proliferation of C57BL/6 and
BALB/c spleen cells (p < 0.01). For C57BL/6 cells, the optimum
amount ranged from 25 µg to 0.39 µg, while in higher (100 and
50 µg) or lower amounts (0.19 and 0.09 µg), no stimulatory effect
was detected. BALB/c spleen cells were shown to be more sen-
sitive to CTE, since a wider range of CTE amounts, from 100
to 0.19 µg, stimulated significant cell proliferation (p < 0.01)
(Fig. 3).
3.3. The effect of CTE inoculation on the relative ratio of
spleen weight vs body weight
The intraperitoneal administration of CTE caused an in-
crease in the relative ratio (spleen weight/body weight) of both
mice strains. On the 5th day afterTCE inoculation, C57BL/6 mice
showed a significant increase (p < 0.001) in spleen weight/
body weight (from 3.89 × 10−3 to 6.30 × 10−3), followed by a
significant reduction (p < 0.001) to basal levels (4.60 × 10−3) by
the 10th day (Fig. 4).
For the BALB/c mice, a gradual significant (p < 0.001) incre-
ment of the relative ratio was observed on the 5th day (from
4.44 × 10−3 to 5.88 × 10−3) and also on the 10th day (7.33 × 10−3)
after CTE inoculation (Fig. 4).
3.4. In vivo effect of CTE inoculation on mice splenocytes
Interestingly, the total number of splenocytes from control
BALB/c mice (143.7 ± 19.6 × 106 cells) was significantly (p < 0.001)
higher than those from control C57BL/6 mice (48.4 ± 7.9 × 106
cells). After CTE administration, C57BL/6 mice showed a sig-
nificant (p < 0.001) increase in splenocyte numbers by the 5th
day (123.3 ± 15.5 × 106 cells), followed by a significant
Fig. 3 – In vitro splenocyte proliferation assay in the presence of CTE. Splenocytes (4 × 105 cells) from non-inoculated
C57BL/6 and BALB/c mice were cultured in 200 µL of RPMI complete medium in the absence (control) or presence of
decreasing amounts of CTE, from 100 µg to 0.09 µg. Cells were pulsed with [H3]-thymidine for 16 h before the culture was
ended. Proliferative activity is represented by scintillations per minute (CPM) and the values are displayed as means ± SD
from three independent experiments. The black bars correspond to cells derived from C57BL/6 mice and the open bars, to
cells from BALB/c mice. Asterisks indicate significance level *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4 – Relative ratio of spleen weight vs body weight
following CTE inoculation. The in vivo effect of CTE on
spleen weight/body weight was evaluated after
intraperitoneal administration of CTE (1 mg) in both
C57BL/6 and BALB/c strains (n = 10, each strain). At the 5th
and 10th day, 5 animals from each strain were sacrificed
and their spleens were removed and weighed to determine
the relative ratio of spleen weight/body weight. The values
represent the means ± SD of 5 animals from control or CTE-
inoculated group. Asterisks indicate significance level
compared to control group: *p < 0.05, **p < 0.01, ***p < 0.001.
Letters also indicate significance level, a, p < 0.001
compared to the 5th day.
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reduction (p < 0.05) by the 10th day (80.8 ± 9.6 × 106 cells) but,
still significantly higher (p < 0.05) than control C57BL/6 mice
(48.4 ± 7.9 × 106 cells). CTE inoculation also resulted in a sig-
nificant increase (p < 0.001) in the number of splenocytes by
the 5th day in BALB/c mice, from 143.7 ± 19.6 to 210 ± 42.4 × 106
cells, which continued to increase up to the 10th day
(214.8 ± 20.9 × 106 cells) (Fig. 5A).
3.5. Quantification of B220+ splenocytes after TCE
administration
To determine the effect of CTE on the B cell population, spleen
cells were probed against anti-B220 monoclonal antibodies. A
significant increase in B220+ cells (p < 0.001) of the C57BL/6
strain was observed on the 5th day (from 26.2 ± 7.8 × 106 cells
to 75.3 ± 6.8 × 106 cells) and persisted up to the 10th day
(p < 0.01), when the total number of B220+ cells (31.2 ± 7.9 × 106
cells) was still significantly higher (p < 0.05) than the control
group. In BALB/c mice, a significant increase (p < 0.01) in the
number of B cells was only observed on the 10th day in com-
parison to the control group (from 74.2 ± 17.9 × 106 cells to
108.2 ± 20.9 cells) (Fig. 5B).
3.6. The effect of CTE inoculation on antibody production
The anti-BrMRBC plaque-forming cells (PFC) were evaluated in
order to establish the frequency of antibody-secreting B cells.
Mice inoculation with CTE resulted in a significant increase of
the anti-autologous-erythrocyte antibody-secreting cells on the
10th day compared to the control group (209 ± 43.8 × 106 cells
and 7 ± 5.6 × 106 cells, respectively) in C57Bl/6 mice. No sig-
nificant variation was observed in the PFC numbers in BALB/c
mice (Fig. 6).
3.7. Proliferation of total bone-marrow cells and B cell
population after CTE inoculation
The intraperitoneal inoculation of CTE resulted in a transient
but non-significant change in the number of bone-marrow cells
in C57BL/6 mice. In BALB/c mice, a gradual increase in the
number of bone-marrow cells was observed, with a signifi-
cant increase on the 10th day (31.3 ± 1.7 × 106 cells; p < 0.001)
compared to both the control (20.2 ± 4.1 × 106 cells) and the 5th
day of theTCE treatment groups (21.3 ± 1.6 × 106 cells) (Table 1).
C57BL/6 immature B cells (B220+IgM−) showed a dynamic
behaviour where, on the 5th day after CTE inoculation, the
number of immature B cells decreased (from 1.6 ± 0.4 × 106 cells
to 0.5 ± 0.2 × 106 cells) (p < 0.001), followed by an increase
(3.4 ± 1.3 × 106 cells) on the 10th day (p < 0.001). In BALB/c mice,
no significant variation of the immature B cell (B220+IgM−) popu-
lation was observed after CTE inoculation.
A similar effect was observed on mature B cells (B220+IgM+)
from both strains. On the 5th day after CTE inoculation, the
number of B220+IgM+cells (0.7 ± 0.2 × 106 cells) from C57BL/6
Fig. 5 – In vivo effect of CTE inoculation on the number of total and B220+ splenocytes. The total number of splenocytes was
determined on the 5th and 10th day after intraperitoneal inoculation of 1 mg CTE (A) and B cells were identified using an
anti-B220 as probe (B). The values represent the means ± SD of 5 animals from the control or CTE-inoculated group.
Asterisks indicate significance level compared to control group: *p < 0.05, **p < 0.01, ***p < 0.001. Letters also indicate
significance level: a, p < 0.001 between the control groups of both strains; b, p < 0.01 compared to the 5th day; c, p < 0.05
compared to the 5th day.
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mice decreased significantly (p < 0.001) compared to the con-
trols (3.3 ± 0.5 × 106 cells). Additionally, a significant (p < 0.01)
increase was observed on the 10th day (2.9 ± 0.9 × 106 cells) com-
pared to the 5th day, but not in the control mice. In BALB/c mice,
no significant variation in the number of mature B220+IgM+ cells
was observed following CTE inoculation (Table 1).
4. Discussion
Taro functional and nutritional properties have been studied
for almost half a century with the first report in 1967 (Lim, 2015;
Rao, Shurpalekar, & Sundaravalli, 1967). Although taro pro-
vides mainly carbohydrates, it is an important source of
proteins, which electrophoretic profiles can change slightly
among different cultivars (Hirai, Sato, & Takayanagi, 1989).
Herein, water-soluble proteins were extracted from taro
corms and the electrophoretic analysis revealed the pres-
ence of three major groups, in accordance with typical profiles
reported previously (Hirai et al., 1993; Pereira et al., 2014), which
includes the presence of two polypeptide bands of around
12 kDa, as well as two of about 22 kDa and two others of ap-
proximately 55 kDa (Fig. 2).
Taro proteins have already been studied, characterized and
evaluated regarding their biological properties (Shewry, 2003).
The amino acid sequence of the 22 kDa polypeptide bands is
homologous to the trypsin inhibitor family found in soy-
beans, winged beans, sweet potato and barley (Hirai et al., 1993)
with potent biotechnological applications in the agricultural
area to protect plants from phytophagous pests and patho-
gens (Mehrabadi, Bandani, & Franco, 2012). The 55 kDa
polypeptide band was identified as an albumin, with pI ranging
from 5.5 to 6.0, although no biological activity was associated
with this band (de Castro, Carneiro, Neshich Dde, & de Paiva,
1992).The 12 kDa polypeptide bands were identified as the sub-
units of the lectin from C. esculenta corms, called tarin (Bezerra
et al., 1995; Pereira et al., 2014; Van Damme et al., 1995) and
were fully characterized by our research group (Pereira et al.,
2015). This protein was extensively associated with impor-
tant biological activities such as anti-insect (Das, Roy, Hess, &
Das, 2013; Roy, Banerjee, Majumder, & Das, 2002; Roy, Gupta,
Hess, Das, & Das, 2014), immunostimulatory (Pereira et al., 2014;
Tulin & Ecleo, 2007) and antimetastatic (Kundu et al., 2012)
properties.
Preliminary studies, performed by this research group, dem-
onstrated that crude taro extract has an in vivo stimulatory effect
on peritoneal macrophages and also enhances their phago-
cytic activity.Those effects were accompanied by an increment
in spleen weights, suggesting that CTE can cause modifica-
tions on other haematopoietic cells (unpublished results).
Additionally, a previous study showed the ability of CTE pro-
teins to stimulate in vitro proliferation of mice spleen and bone
marrow cells (Tulin & Ecleo, 2007).
The present study performed a further investigation re-
garding not only the in vitro but also the in vivo effect of CTE
on haematopoietic cells from mice spleen and bone marrow,
with special attention to B lymphocytes.
The results confirmed that CTE is able to stimulate
haematopoietic cells both in vitro and in vivo. Not surpris-
ingly, the in vitro proliferation assays (Fig. 3) resulted in a dose-
Fig. 6 – Number of antibody-secreting B cells caused by CTE
inoculation. One milligram of CTE was administered to
C57BL/6 and BALB/c strains (n = 10, each strain) by
intraperitoneal route. On the 5th and 10th day after
inoculation, 5 animals from the control and CTE-inoculated
group were sacrificed and their spleen cells were retrieved
to perform the plaque-forming cell (PFC) assay. The values
represent the means ± SD of 5 animals from control or CTE-
inoculated group. Asterisks indicate significance level:
*p < 0.05, **p < 0.01, ***p < 0.001.
Table 1 – Phenotype analysis of bone marrow B cells from CTE-inoculated mice.
Mice strain Time point Total bone marrow (×106) cells B220+ IgM− (×106) cells B220+ IgM+ (×106) cells
C57BL/6 Day 0 24.8 ± 5.8 1.6 ± 0.4 3.3 ± 0.3
Day 5 23.0 ± 6.2 0.5 ± 0.2*** 0.7 ± 0.3***
Day 10 29.5 ± 6.8 3.4 ± 1.3*,a 2.9 ± 1.1b
BALB/c Day 0 20.2 ± 4.1 5.7 ± 2.2 2.7 ± 1.0
Day 5 21.3 ± 1.6 4.9 ± 1.3 3.7 ± 1.4
Day 10 31.3 ± 2.9***,a 4.5 ± 0.8 1.7 ± 0.5
In vivo effect of CTE on bone marrow B cells. Mice (C57BL/6 and BALB/c) were inoculated with 1 mg of CTE by intraperitoneal route. Five and
ten days after inoculation, bone-marrow cells were obtained from the femoral bone.The number of total cells were counted and probed against
anti-B220 and anti-IgM antibodies. The values represent the means ± SD of 5 animals from control or CTE-inoculated group. Asterisks indicate
significance level: *p < 0.05 or ***p < 0.001. Letters indicate significance level: ap < 0.001 compared to the 5th day, bp < 0.01 compared to the 5th
day.
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dependent curve and are in accordance with the literature
(Tulin & Ecleo, 2007). In this study, a wider range of CTE
concentrations was used (from 100 to 0.09 µg), where
concentrations ranging from 0.78 to 25 µg stimulated
splenocyte proliferation, while higher concentrations, between
50 and 100 µg, inhibited the proliferative activity in C57BL/6
mice.
Immunostimulatory effects have been constantly associ-
ated to active plant proteins classified as lectins (Ashraf & Khan,
2003) for at least 5 decades (Nowell, 1960).These molecules are
characterized by their ability to bind specifically to carbohy-
drates, triggering a variety of biological properties including
the stimulatory effect on the immune system (Hivrale & Ingale,
2013). As aforementioned, a lectin, named tarin, is present in
the CTE preparation and accounts for 58% of the total visual-
ized proteins. Previous studies revealed that CTE shows
haemagglutinating activity (unpublished results), which typi-
cally detects the presence of lectin activity, suggesting the
participation of such protein in the biological response de-
scribed herein. In a previous study, the purified form of taro
lectin was also able to induce in vitro splenocyte proliferation
in a dose-dependent manner (Pereira et al., 2014), as also shown
in the present study.Typically, immunostimulatory lectins, also
called mitogenic lectins, generate dose-dependent curves
(Eijsvoogel, 2012), consistent with the results obtained herein.
The best-known immunostimulatory lectins are phytohae-
magglutinin (PHA) from the kidney bean (Phaseolus vulgaris),
concanavalin A (Con A) from the jackbean (Canavalia ensiformis)
and pokeweed mitogen (PWM) from the roots of pokeweed
(Phytolacca americana). While the first two lectins mainly acti-
vate T lymphocytes, the latter activates both T and B cells
(Shanmugham et al., 2006).
Intraperitoneal inoculation of CTE caused an increase of
the spleen weight/body weight index (Fig. 4) in both mouse
strains, reflecting the increment in total splenocytes and
B220+ splenocytes (Fig. 5), but the dynamics of this CTE effect
differed within the strains. While in C57BL/6 mice these
alterations were transient, reaching a peak on the 5th day
and declining by the 10th day, in BALB/c mice these
parameters increased gradually until the 10th day. This dis-
similarity is, probably, caused by a difference in the cytokine
profile of both mice strains inherent to their distinct genetic
background.
The proliferative potential of the purified lectin from taro
has also been previously studied, showing that this protein is
also able to increase significantly the number of total
splenocytes and B220+ cells on the 5th day after the intraperi-
toneal inoculation of C57BL/6 mice (Pereira et al., 2014). These
findings reinforce the participation of lectin in the immune re-
sponse shown herein.
Interestingly, after CTE inoculation in C57BL/6 mice,
splenocytes were stimulated to a significant production of an-
tibodies on the 5th day, when the number of B220+ splenocytes
was significantly increased. B lymphocytes were not just stimu-
lated to a proliferative state but were also activated by CTE,
leading to antibody release.
Moreover, CTE was shown to have a distinct effect on B1
lymphocytes, which differ from B2 lymphocytes by their
ability to produce natural antibodies including, those against
senescent erythrocytes (anti-BrMRBC) (Hardy & Hayakawa,
2005). The results presented herein indicate that CTE was
able to induce the proliferation of B2 cells (Fig. 5) derived
from both C57BL/6 and BALB/c, while acting differently on B1
lymphocytes (Fig. 6). The fact that CTE had a strong effect on
B1 cells from C57BL/6 but not from BALB/c mice (Fig. 6)
suggests that the genetic background of the mice strains
may affect B-cell activation, and points to the importance of
further examination of B-cell behaviour in the context of
plant immunostimulators.
The effect of CTE on total bone-marrow cells occurred after
10 days for both strains, although the increase was only sig-
nificant for BALB/c mice. A transient reduction of B220+IgM−
(immature B cells) and B220+IgM+ (mature B cells) in the bone
marrow with a concomitant increase of B220+ lymphocytes in
the spleen of both strains was observed.These changes suggest
that CTE acts on the transient cell populations during the dif-
ferentiation process, and/or on the compartmental mobilization
of B220+ cells to the spleen. However, the distinct dynamics that
occurred within the same time frame do not allow for the con-
clusion of how and where the reduced bone marrow B220+ cells
would be destined.
Another recent study by our research group showed that
the lectin from taro binds with low or no affinity to free
mannose, but is able to strongly bind to complex and high-
mannose N-glycans. Among the ligands that best interact with
this lectin are the epitopes designated Lewisy/CD174 (Fucα1-
2Galβ1-4[Fucα1-3]GlcNAcβ1-) and H2/CD173 (Fucα1-2Galβ1-
4GlcNAcβ1-) antigens (Pereira et al., 2015). These antigens are
found in human CD34+ haematopoietic progenitor cells (Cao,
Merling, Karsten, & Schwartz-Albiez, 2001) and in peripheral
blood granulocytes (Dettke, Palfi, & Loibner, 2000). Glycans with
fucosylated sites play an important role in cell–cell and cell–
matrix interaction, differentiation, proliferation and apoptosis.
Both antigens (CD174 and CD173) allow the recirculation of lym-
phocytes from the bloodstream into lymphatic organs and the
interaction between haematopoietic progenitor cells and bone-
marrow stromal cells (Cao et al., 2001).The expression of CD34
on the surface of haematopoietic progenitor cells character-
izes a heterogeneous population with multipotent capacity to
reconstitute the myelo-lymphopoietic system in a supralethal
irradiated host (Stella et al., 1995).
The immunostimulatory effects observed in this study
are, possibly, the result of the participation of tarin through
the specific binding to CD34+ progenitor cells, favouring B
lymphopoiesis. The participation of other factors and/or
compounds, however, cannot be discarded. However,
further investigation should be conducted to determine the
real contribution of each component to the B proliferation
response.
Taro corms are, undoubtedly, a potent natural source of
immunostimulatory molecules.The stimulation of the immune
system by CTE can positively contribute to health and well-
being maintenance, since it can be applied to reverse an
immunosuppressive status caused by infectious agents, che-
motherapeutic agents or even psychological conditions.
Moreover, CTE can confer protection against several diseases
since it stimulates the proliferation of total haematopoietic and
B cells, contributing to the improvement in the immune re-
sponse. Such molecules represent powerful candidates as new
additives for food and pharmaceutical industries.
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5. Conclusions
Taro corms are a natural source of bioactive proteins,which act
as immunostimulators on total bone marrow and spleen cells
from distinct mice strains.The proliferation of mice B220+ lym-
phocytes of both organswas also stimulated by CTE inoculation.
The increment in B220+ cells from the spleens was accompa-
niedbyadecreaseofmature (B220+IgM+) and immature (B220+IgM−)
lymphocytes in the bone marrow, suggesting the early mobili-
zation of these cells to the spleen. The production of primary
antibodies by B220+ splenocytes indicated the activation of B1
cells by CTE. Total splenocytes were also stimulated in vitro by
CTE in a dose-dependent manner. The in vivo effects of CTE in
both murine models encouraged us to test taro active proteins
on the recovery of the immune status of immunosuppressed
mice. Future studies need to be conducted in order to explore
the mechanisms of CTE-induced cell activation.
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